Oral Beta-blocker in Problematic Infantile Hemangioma
Rashed N AlHasan1, Lamees Arabiyat2, Hamad M Ammar1
1Department of Plastic Surgery & Burns, Bahrain Defense Force Royal Medical Services, Bahrain.
Plastic and Reconstructive Surgery. Global Open
|December 9, 2021
Summary
Oral propranolol effectively treated a challenging periorbital infantile hemangioma in a young child. This treatment led to significant lesion involution with no rebound growth, demonstrating its safety and efficacy.
Area of Science:
- Vascular Biology
- Pediatric Dermatology
- Clinical Pharmacology
Background:
- Infantile hemangiomas are common benign vascular tumors, frequently occurring in the head and neck.
- Problematic infantile hemangiomas can pose treatment challenges due to functional or aesthetic concerns.
- Treatment decisions for periorbital infantile hemangiomas require careful consideration.
Observation:
- A case study involved a 3-year, 7-month-old girl with a periorbital infantile hemangioma.
- The patient received oral propranolol treatment starting at 4 months of age.
- Treatment involved specific dosages and a gradual dose-tapering schedule.
Findings:
- The periorbital infantile hemangioma showed marked involution.
- No significant side effects were observed during the 13-month treatment period.
- No rebound growth was reported nearly 2 years after treatment cessation.
Implications:
- Oral propranolol can be a safe and effective single-modality treatment for problematic infantile hemangiomas.
- This approach may obviate the need for surgical intervention in select cases.
- Beta-blocker therapy offers a promising non-surgical option for managing infantile hemangiomas.
More Related Videos
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.1K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.1K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
775
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
775
01:28Antihypertensive Drugs: Types of β-Blockers
1.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.0K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
238
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
918
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
918
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
277
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
277